Search
Trabodenoson
go.drugbank.com/drugs/DB13122InvestigationalTrabodenoson has been used in trials studying the treatment of Ocular Hypertension (OHT) and Primary Open-Angle Glaucoma (POAG).
Anecortave
go.drugbank.com/drugs/DB12081ExperimentalAnecortave is under investigation in clinical trial NCT00691717 (Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular Hypertension).
Setogepram
go.drugbank.com/drugs/DB15447InvestigationalSetogepram is under investigation in clinical trial NCT03184584 (Open-Label Rollover Study of PBI 4050 in Subjects With Alström Syndrome).
NV-5138
go.drugbank.com/drugs/DB19180InvestigationalNV-5138 is under investigation in clinical trial NCT06235905 (Open-label of SPN-820 in Adults With Major Depressive Disorder).
YCT-529
go.drugbank.com/drugs/DB21748InvestigationalYCT-529 is under investigation in clinical trial NCT06542237 (Open Label, Repeat Dose Study Evaluating YCT-529 in Healthy Males).
Povetacicept
go.drugbank.com/drugs/DB18996InvestigationalPovetacicept is under investigation in clinical trial NCT05757570 (An Open-label Study of Povetacicept in Subjects With Autoimmune Cytopenias).
Camizestrant
go.drugbank.com/drugs/DB19218ApprovedInvestigational[L64094,L64107] It binds the ligand binding domain of ERα, antagonizing ERα encoded by both wild-type and mutated *ESR1* and inducing proteasome-dependent degradation of the receptor without agonizing
Eplontersen
go.drugbank.com/drugs/DB16199ApprovedInvestigationaltransthyretin-mediated amyloidosis is caused primarily by pathogenic variants of the TTR gene, leading to the formation and thus accumulation of insoluble and misfolded amyloid in multiple organs, although wild-type
Branaplam
go.drugbank.com/drugs/DB14918InvestigationalBranaplam is under investigation in clinical trial NCT02268552 (An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA)).
Sodium zirconium cyclosilicate
go.drugbank.com/drugs/DB14048ApprovedInvestigational[L2933] Approval of the medication is supported by data from three double-blind, placebo-controlled trials and two open-label trials which showed that the onset of action was approximately 1.0 hour and